Adalvo is delighted to announce that our DCP slot for Vortioxetine Film-Coated Tablets has been booked for the 15th July 2022.
Our product has been developed based on the reference brand Brintellix 20mg which is indicated for the treatment of Anti-Depression and sold at around $1.7bn in 2021, according to IQVIA. This product is being developed as part of a strategic collaboration with one of our partners.
Based on this positive progress, we will align all our partners for filing until 20th June 2022, the present deadline for our DCP’s enrollments.
The selected partners will get access to what we expect to be a timely first-to-file opportunity/ first-to-market companies in all our major markets.
Our Adalvo bees will support you throughout the process!
Partner up now!
At Adalvo, there are no half measures – we are always on target. When your mission is to be faster and stronger than your competitors, you need a winning team driving your vision forward.
ajish.rajan@adalvo.com – Central & Eastern Europe, Russia & CIS
aitor.alferez@adalvo.com – South Europe & Israel
jose.rendueles@adalvo.com- North Europe, APAC and MENA,
margarida.neves@adalvo.com – Brazil
paulo.rodriguez@adalvo.com – LATAM (Exc. Brazil)
supreet.sharma@adalvo.com – UK/Ireland, North America & South Africa
arni.baldursson@adalvo.com - Head of Global BD&L
Disclaimer: Vortioxetine which is subject to patent protection are currently not offered or made available in countries where patents are in force.